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or squamous intraepithelial lesion (SIL), 21.3% were lost to follow-up. The average duration of follow-up was 3.4 years.
Analysis of effectiveness
The primary health outcomes studied were diagnosis after rescreening and risk of cervical disease.
Effectiveness results
The number of rescreening diagnoses of ASCUS, AGUS, or SIL was 417 (2.6% of all rescreened smears). Of patients with a rescreening diagnosis of ASCUS, AGUS, or SIL, 21.3% were lost to follow-up, 41.7% had benign findings at follow-up, 36.9% had a preneoplastic or neoplastic lesion, and 11.3% had high-grade SIL or adenocarcinoma in situ (AIS). Of the 5,396 patients at high risk and 10,792 at low risk, 0.4% and 0.04%, respectively, had an HSIL or AIS at follow-up.
Clinical conclusions
Not reported.
Modelling
A decision model was used to determine the cost-effectiveness of the rescreening strategies.
Outcomes assessed in the review
The review assessed the following outcomes: life expectancy data and probability data.
Study designs and other criteria for inclusion in the review
Not stated.
Sources searched to identify primary studies
Effectiveness data were obtained from the Surveillance Epidemiologic and End Results Program, the National Center for Health Statistics and a MEDLINE search.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Methods of combining primary studies
Investigation of differences between primary studies
